Computational modeling and simulation of the Bcl-2 family: Paving the way for rational drug design

Current Medicinal Chemistry

Volumn 19, Issue 36, 2012, Pages 6081-6094

  Rosas Trigueros, J L ^a,b   Ilizaliturri Flores, I ^a   Benitez Cardoza C G ^a   Correa Basurto, J ^a,b   Zamorano Carrillo, A ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b Grupo Interdisciplinario de Inteligencia Artificial Aplicada   (Germany)

Author keywords

Apoptosis; Bcl 2; Bioinformatics; Cancer; Molecular modeling; Protein protein interaction; Structure based drug design

Indexed keywords

CYTOCHROME C; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN C JUN; PROTEIN P53;

APOPTOSIS; CRYSTAL STRUCTURE; DRUG DESIGN; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DATABASE; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

DATABASES, PROTEIN; DRUG DESIGN; ENDOPLASMIC RETICULUM; HUMANS; MITOCHONDRIA; MOLECULAR DOCKING SIMULATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84871302321     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712804485656     Document Type: Review

References (171)

1. Kerr, J. F.; Wyllie, A. H.; Currie, A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 1972, 26, (4), 239-257.
2. Kroemer, G.; Galluzzi, L.; Vandenabeele, P.; Abrams, J.; Alnemri, E. S.; Baehrecke, E. H.; Blagosklonny, M. V.; El-Deiry, W. S.; Golstein, P.; Green, D. R.; Hengartner, M.; Knight, R. A.; Kumar, S.; Lipton, S. A.; Malorni, W.; Nunez, G.; Peter, M. E.; Tschopp, J.; Yuan, J.; Piacentini, M.; Zhivotovsky, B.; Melino, G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ, 2008, 16, (1), 3-11.
3. Strasser, A.; O'Connor, L.; Dixit, V. M. Apoptosis signaling. Annu Rev Biochem, 2000, 69, (1), 217-245.
4. Hotchkiss, R. S.; Strasser, A.; McDunn, J. E.; Swanson, P. E. Cell death. N Engl J Med, 2009, 361, (16), 1570-1583.
5. Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: The Next Generation. Cell, 2011, 144, (5), 646-674.
6. Tang, Y.; Hamed, H. A.; Cruickshanks, N.; Fisher, P. B.; Grant, S.; Dent, P. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Mol Pharmacol, 2012, 81, (4), 527-540.
7. Kelly, P. N.; Strasser, A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ, 2011, 18, (9), 1414-1424.
8. Mazars, A.; Geneste, O.; Hickman, J. The Bcl-2 family of proteins as drug targets. J Soc Biol, 2005, 199, (3), 253-265.
9. Smits, C.; Czabotar, P. E.; Hinds, M. G.; Day, C. L. Structural plasticity underpins promiscuous binding of the prosurvival protein A1. Structure, 2008, 16, (5), 818-829.
10. Meng, X. Y. Y.; Zhang, H. X. X.; Mezei, M.; Cui, M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des, 2011, 7, (2), 146-157.
11. Asthagiri, A. R.; Arkin, A. P. Computational methods in cell biology, Volume 110; Academic Press; 2012.
12. Mak, H. C. Trends in computational biology-2010. Nat Biotechnol, 2011, 29, (1), 45.
13. Chua, H. N.; Roth, F. P. Discovering the Targets of Drugs via Computational Systems Biology. J Biol Chem, 2011, 286, (27), 23653-23658.
14. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell, 2000, 100, (1), 57-70.
15. Marazziti, D.; Baroni, S.; Picchetti, M.; Landi, P.; Silvestri, S.; Vatteroni, E.; Catena Dell'Osso, M. Psychiatric disorders and mitochondrial dysfunctions. Eur Rev Med Pharmacol Sci, 2012, 16, (2), 270-275.
16. Agostini, M.; Tucci, P.; Melino, G. Cell death pathology: perspective for human diseases. Biochem Biophys Res Commun, 2011, 414, (3), 451-455.
17. Plati, J.; Bucur, O.; Khosravi-Far, R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb), 2011, 3, (4), 279-296.
18. Ulukaya, E.; Acilan, C.; Yilmaz, Y. Apoptosis: why and how does it occur in biology? Cell Biochem Funct, 2011, 29, (6), 468-480.
19. Chipuk, J. E.; Moldoveanu, T.; Llambi, F.; Parsons, M. J.; Green, D. R. The BCL-2 family reunion. Mol Cell, 2010, 37, (3), 299-310.
20. Kvansakul, M.; Yang, H.; Fairlie, W. D.; Czabotar, P. E.; Fischer, S. F.; Perugini, M. A.; Huang, D. C.; Colman, P. M. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ, 2008, 15, (10), 1564-1571.
21. Giam, M.; Huang, D. C.; Bouillet, P. BH3-only proteins and their roles in programmed cell death. Oncogene, 2008;27 Suppl 1(S1), S128-S136.
22. Adams, J. M.; Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science, 1998, 281, (5381), 1322-1326.
23. Lama, D.; Sankararamakrishnan, R. Identification of core structural residues in the sequentially diverse and structurally homologous Bcl-2 family of proteins. Biochemistry, 2010, 49, (11), 2574-2584.
24. Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t (14;18) chromosome translocation. Science, 1984, 226, (4678), 1097-1099.
25. Son, Y. O. O.; Heo, J. S. S.; Kim, T. G. G.; Jeon, Y. M. M.; Kim, J. G. G.; Lee, J. C. C. Over-expression of JunB inhibits mitochondrial stress and cytotoxicity in human lymphoma cells exposed to chronic oxidative stress. BMB reports, 2010, 43, (1), 57-61.
26. Thrumurthy, S. G. G.; Lewis, C. J. J.; Pritchard, S.; Armstrong, G.; Attwood, S. E. A. E. Reply to letter to the editor: Re: Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies (Online First). Surg Endosc, 2012, 26, (1), 291-292.
27. Wesarg, E.; Hoffarth, S.; Wiewrodt, R.; Kröll, M.; Biesterfeld, S.; Huber, C.; Schuler, M. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer, 2007, 121, (11), 2387-2394.
28. Deng, X.; Kornblau, S. M.; Ruvolo, P. P.; May, W. S. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J Natl Cancer Inst Monogr, 2001;28, 30-37.
29. Hinds, M. G.; Day, C. L. Regulation of apoptosis: uncovering the binding determinants. Curr Opin Struct Biol, 2005, 15, (6), 690-699.
30. Dewson, G.; Kluck, R. M. Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. J Cell Sci, 2009;122(Pt 16), 2801-2808.
31. Kim, H.; Tu, H. C. C.; Ren, D.; Takeuchi, O.; Jeffers, J. R.; Zambetti, G. P.; Hsieh, J. J.; Cheng, E. H. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell, 2009, 36, (3), 487-499.
32. Karbowski, M.; Norris, K. L.; Cleland, M. M.; Jeong, S. Y.; Youle, R. J. Role of Bax and Bak in mitochondrial morphogenesis. Nature, 2006, 443, (7112), 658-662.
33. Bleicken, S.; Classen, M.; Padmavathi, P. V.; Ishikawa, T.; Zeth, K.; Steinhoff, H. J. J.; Bordignon, E. Molecular details of Bax activation, oligomerization, and membrane insertion. J Biol Chem, 2010, 285, (9), 6636-6647.
34. Annis, M. G.; Soucie, E. L.; Dlugosz, P. J.; Cruz-Aguado, J. A.; Penn, L. Z.; Leber, B.; Andrews, D. W. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J, 2005, 24, (12), 2096-2103.
35. Chipuk, J. E.; McStay, G. P.; Bharti, A.; Kuwana, T.; Clarke, C. J.; Siskind, L. J.; Obeid, L. M.; Green, D. R. Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell, 2012, 148, (5), 988-1000.
36. Lucken-Ardjomande, S.; Montessuit, S.; Martinou, J. C. C. Contributions to Bax insertion and oligomerization of lipids of the mitochondrial outer membrane. Cell Death Differ, 2008, 15, (5), 929-937.
37. Zhang, Z.; Zhu, W.; Lapolla, S. M.; Miao, Y.; Shao, Y.; Falcone, M.; Boreham, D.; McFarlane, N.; Ding, J.; Johnson, A. E.; Zhang, X. C.; Andrews, D. W.; Lin, J. Bax forms an oligomer via separate, yet interdependent, surfaces. J Biol Chem, 2010, 285, (23), 17614-17627.
38. Dewson, G.; Kratina, T.; Sim, H. W.; Puthalakath, H.; Adams, J. M.; Colman, P. M.; Kluck, R. M. To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. Mol Cell, 2008, 30, (3), 369-380.
39. Schendel, S. L.; Montal, M.; Reed, J. C. Bcl-2 family proteins as ion-channels. Cell Death Differ, 1998, 5, (5), 372-380.
40. Antonsson, B.; Conti, F.; Ciavatta, A.; Montessuit, S.; Lewis, S.; Martinou, I.; Bernasconi, L.; Bernard, A.; Mermod, J. J.; Mazzei, G.; Maundrell, K.; Gambale, F.; Sadoul, R.; Martinou, J. C. Inhibition of Bax channel-forming activity by Bcl-2. Science, 1997, 277, (5324), 370-372.
41. Schlesinger, P. H.; Gross, A.; Yin, X. M.; Yamamoto, K.; Saito, M.; Waksman, G.; Korsmeyer, S. J. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci U S A, 1997, 94, (21), 11357-11362.
42. Lee, E. F.; Dewson, G.; Smith, B. J.; Evangelista, M.; Pettikiriarachchi, A.; Dogovski, C.; Perugini, M. A.; Colman, P. M.; Fairlie, W. D. Crystal Structure of a BCL-W Domain-Swapped Dimer: Implications for the Function of BCL-2 Family Proteins. Structure, 2011, 19, (10), 1467-76.
43. Walensky, L. D.; Gavathiotis, E. BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem Sci, 2011, 36, (12), 642-652.
44. Gavathiotis, E.; Reyna, D. E.; Davis, M. L.; Bird, G. H.; Walensky, L. D. BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol Cell, 2010, 40, (3), 481-492.
45. Oh, K. J. J.; Singh, P.; Lee, K.; Foss, K.; Lee, S.; Park, M.; Lee, S.; Aluvila, S.; Park, M.; Singh, P.; Kim, R. S.; Symersky, J.; Walters, D. E. Conformational changes in BAK, a pore-forming proapoptotic Bcl-2 family member, upon membrane insertion and direct evidence for the existence of BH3-BH3 contact interface in BAK homo-oligomers. J Biol Chem, 2010, 285, (37), 28924-28937.
46. Lee, E. F.; Czabotar, P. E.; Yang, H.; Sleebs, B. E.; Lessene, G.; Colman, P. M.; Smith, B. J.; Fairlie, W. D. Conformational changes in Bcl-2 prosurvival proteins determine their capacity to bind ligands. J Biol Chem, 2009, 284, (44), 30508-30517.
47. Lalier, L.; Cartron, P. F. F.; Olivier, C.; Logé, C.; Bougras, G.; Robert, J. M. M.; Oliver, L.; Vallette, F. M. Prostaglandins antagonistically control Bax activation during apoptosis. Cell Death Differ, 2011, 18, (3), 528-537.
48. Chipuk, J. E.; Kuwana, T.; Bouchier-Hayes, L.; Droin, N. M.; Newmeyer, D. D.; Schuler, M.; Green, D. R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science, 2004, 303, (5660), 1010-1014.
49. Deng, X.; Gao, F.; Flagg, T.; Anderson, J.; May, W. S. Bcl2's flexible loop domain regulates p53 binding and survival. Mol Cell Biol, 2006, 26, (12), 4421-34.
50. Khaled, A. R.; Kim, K.; Hofmeister, R.; Muegge, K.; Durum, S. K. Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. Proc Natl Acad Sci U S A, 1999, 96, (25), 14476-14481.
51. Kutuk, O.; Letai, A. Regulation of Bcl-2 family proteins by posttranslational modifications. Curr Mol Med, 2008, 8, (2), 102-118.
52. Bogner, C.; Leber, B.; Andrews, D. W. Apoptosis: embedded in membranes. Curr Opin Cell Biol, 2010, 22, (6), 845-851.
53. Yethon, J. A.; Epand, R. F.; Leber, B.; Epand, R. M.; Andrews, D. W. Interaction with a membrane surface triggers a reversible conformational change in Bax normally associated with induction of apoptosis. J Biol Chem, 2003, 278, (49), 48935-48941.
54. Christenson, E.; Merlin, S.; Saito, M.; Schlesinger, P. Cholesterol effects on BAX pore activation. J Mol Biol, 2008, 381, (5), 1168-1183.
55. Lucken-Ardjomande, S.; Montessuit, S.; Martinou, J. C. C. Bax activation and stress-induced apoptosis delayed by the accumulation of cholesterol in mitochondrial membranes. Cell Death Differ, 2008, 15, (3), 484-493.
56. Zhao, P.; Turdi, S.; Dong, F.; Xiao, X.; Su, G.; Zhu, X.; Scott, G. I.; Ren, J. Cardiac-specific overexpression of insulin-like growth factor I (IGF-1) rescues lipopolysaccharide-induced cardiac dysfunction and activation of stress signaling in murine cardiomyocytes. Shock, 2009, 32, (1), 100-107.
57. Lee, G. H.; Kim, H. K.; Chae, S. W.; Kim, D. S.; Ha, K. C.; Cuddy, M.; et al. Bax inhibitor-1 regulates endoplasmic reticulum stress-associated reactive oxygen species and heme oxygenase-1 expression. J Biol Chem, 2007, 282, (30), 21618-28.
58. Kuwana, T.; Mackey, M. R.; Perkins, G.; Ellisman, M. H.; Latterich, M.; Schneiter, R.; Green, D. R.; Newmeyer, D. D. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell, 2002, 111, (3), 331-342.
59. Terrones, O.; Antonsson, B.; Yamaguchi, H.; Wang, H. G. G.; Liu, J.; Lee, R. M.; Herrmann, A.; Basañez, G. Lipidic pore formation by the concerted action of proapoptotic BAX and tBID. J Biol Chem, 2004, 279, (29), 30081-30091.
60. Lucken-Ardjomande, H. S. Cholesterol, cardiolipin, and mitochondria permeabilisation. Anticancer Agents Med Chem, 2012, 12, (4), 329-339.
61. Schug, Z. T.; Gottlieb, E. Cardiolipin acts as a mitochondrial signalling platform to launch apoptosis. Biochim Biophys Acta, 2009, 1788, (10), 2022-2031.
62. Kim, T. H. H.; Zhao, Y.; Ding, W. X. X.; Shin, J. N. N.; He, X.; Seo, Y. W. W.; Chen, J.; Rabinowich, H.; Amoscato, A. A.; Yin, X. M. Bid-cardiolipin interaction at mitochondrial contact site contributes to mitochondrial cristae reorganization and cytochrome C release. Mol Biol Cell, 2004, 15, (7), 3061-3072.
63. Lutter, M.; Fang, M.; Luo, X.; Nishijima, M.; Xie, X.; Wang, X. Cardiolipin provides specificity for targeting of tBid to mitochondria. Nat Cell Biol, 2000, 2, (10), 754-761.
64. Letai, A.; Bassik, M. C.; Walensky, L. D.; Sorcinelli, M. D.; Weiler, S.; Korsmeyer, S. J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2002, 2, (3), 183-192.
65. Kuwana, T.; Bouchier-Hayes, L.; Chipuk, J. E.; Bonzon, C.; Sullivan, B. A.; Green, D. R.; Newmeyer, D. D. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell, 2005, 17, (4), 525-535.
66. Mérino, D.; Giam, M.; Hughes, P. D.; Siggs, O. M.; Heger, K.; O'Reilly, L. A.; Adams, Jerry M.; Strasser, A.; Lee, E. F.; Fairlie, W. D.; Bouillet, P. The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol, 2009, 186, (3), 355-362.
67. Chipuk, J. E.; Bouchier-Hayes, L.; Kuwana, T.; Newmeyer, D. D.; Green, D. R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science, 2005, 309, (5741), 1732-5.
68. Billard, C. Development of Noxa-like BH3 Mimetics for Apoptosis-Based Therapeutic Strategy in Chronic Lymphocytic Leukemia. Mol Cancer Res, 2012, 10, (6), 673-676.
69. Lee, E. F.; Smith, B. J.; Horne, W. S.; Mayer, K. N.; Evangelista, M.; Colman, P. M.; Gellman, S. H.; Fairlie, W. D. Structural basis of Bcl-xL recognition by a BH3-mimetic α-β-peptide generated by sequence-based design. Chembiochem, 2011, 12, (13), 2025-2032.
70. Pinto, M.; Orzaez, M. M.; Delgado-Soler, L.; Perez, J. J.; Rubio-Martinez, J. Rational design of new class of BH3-mimetics as inhibitors of the Bcl-xL protein. J Chem Inf Model, 2011, 51, (6), 1249-1258.
71. Kim, D. S.; Sohn, E. J.; Kim, D. W.; Kim, Y. N.; Eom, S. A.; Yoon, G. H.; Cho, S.; Lee, S.; Hwang, H. S.; Cho, Y. S.; Park, J.; Eum, W. S.; Choi, S. Y. PEP-1-p18 prevents neuronal cell death by inhibiting oxidative stress and Bax expression. BMB Rep, 2012, 45, (9), 532-7.
72. Liu, N. S.; Du, X.; Lu, J.; He, B. P. Diva reduces cell death in response to oxidative stress and cytotoxicity. PLoS One, 2012, 7, (8), e43180.
73. Edlich, F.; Banerjee, S.; Suzuki, M.; Cleland, M. M.; Arnoult, D.; Wang, C.; Neutzner, A.; Tjandra, N.; Youle, R. J. Bcl-x (L) retrotranslocates Bax from the mitochondria into the cytosol. Cell, 2011, 145, (1), 104-116.
74. Wysoczanski, P.; Mart, R. J.; Loveridge, E. J.; Williams, C.; Whittaker S. B. M. B.; Crump, M. P.; et al. NMR Solution Structure of a Photoswitchable Apoptosis Activating Bak Peptide Bound to Bcl-x (L). J Am Chem Soc, 2012, 134, (18), 7644-7647.
75. Cheng, Z.; Yang, N.; Liang, W.; Yan, X.; Li, L.; Pan, L. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells. Leuk Lymphoma, 2012, 53, (7), 1383-1389.
76. Pérez-Rodríguez, R.; Fuentes, M. P.; Oliván, A. M.; Martínez-Palacián, A.; Roncero, C.; González, M. P.; Oset-Gasque, M. J. Mechanisms of nitric oxide-induced apoptosis in bovine chromaffin cells: Role of mitochondria and apoptotic proteins. J Neurosci Res, 2007, 85, (10), 2224-2238.
77. Seminara, A. R.; Ruvolo, P. P.; Murad, F. LPS/IFNgamma-induced RAW 264.7 apoptosis is regulated by both nitric oxide-dependent and -independent pathways involving JNK and the Bcl-2 family. Cell Cycle, 2007, 6, (14), 1772-1778.
78. Samraj, A. K.; Stroh, C.; Fischer, U.; Schulze-Osthoff, K. The tyrosine kinase Lck is a positive regulator of the mitochondrial apoptosis pathway by controlling Bak expression. Oncogene, 2006, 25, (2), 186-197.
79. Morales, A. P.; Carvalho, A. C. P.; Monteforte, P. T.; Hirata, H.; Han, S. W.; Hsu, Y. T.; Smaili, S. S. Endoplasmic Reticulum Calcium Release Engages Bax Translocation in Cortical Astrocytes. Neurochem Res, 2011, 36, (5), 829-838.
80. Sheikh, M. S.; Huang, Y., TRAIL death receptors, Bcl-2 protein family, and endoplasmic reticulum calcium pool. Vitam Horm, 2004;67, 169-188.
81. Shoshan-Barmatz, V.; Israelson, A.; Brdiczka, D.; Sheu, S. S. The voltagedependent anion channel (VDAC): function in intracellular signalling, cell life and cell death. Curr Pharm Des, 2006, 12, (18), 2249-2270.
82. Chan, G.; Nogalski, M. T.; Stevenson, E. V.; Yurochko, A. D. Human cytomegalovirus induction of a unique signalsome during viral entry into monocytes mediates distinct functional changes: a strategy for viral dissemination. J Leukoc Biol, 2012, 92, (4), 743-752.
83. Chan, G.; Nogalski, M. T.; Bentz, G. L.; Smith, M. S.; Parmater, A.; Yurochko, A. D. PI3K-dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by epidermal growth factor receptor and inhibits apoptosis in short-lived monocytes. J Immunol, 2010, 184, (6), 3213-3222.
84. Bhuiyan, M. I. H.; Jung, S. Y.; Kim, H. J.; Lee, Y. S.; Jin, C. Major role of the PI3K/Akt pathway in ischemic tolerance induced by sublethal oxygenglucose deprivation in cortical neurons in vitro. Arch Pharm Res, 2011, 34, (6), 1023-34.
85. Haddad, J. J. The role of Bax/Bcl-2 and pro-caspase peptides in hypoxia/reperfusion-dependent regulation of MAPK (ERK): discordant proteomic effect of MAPK (p38). Protein Pept Lett, 2007, 14, (4), 361-71.
86. Nakka, V. P. P.; Gusain, A.; Mehta, S. L.; Raghubir, R. Molecular mechanisms of apoptosis in cerebral ischemia: multiple neuroprotective opportunities. Mol Neurobiol, 2008, 37, (1), 7-38.
87. Di Tommaso, P.; Moretti, S.; Xenarios, I.; Orobitg, M.; Montanyola, A.; Chang, J. M. M.; Taly, J. F.; Notredame, C. T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension. Nucleic Acids Res, 2011;39(Web Server issue), W13-W17.
88. O'Neill, J. W.; Manion, M. K.; Maguire, B.; Hockenbery, D. M. BCL-XL dimerization by three-dimensional domain swapping. J Mol Biol, 2006, 356, (2), 367-81.
89. Dewson, G.; Ma, S.; Frederick, P.; Hockings, C.; Tan, I.; Kratina, T.; Kluck, R. M. Bax dimerizes via a symmetric BH3:groove interface during apoptosis. Cell Death Differ, 2011, 19, (4), 661-670.
90. Anderson, M.; Blowers, D.; Hewitt, N.; Hedge, P.; Breeze, A.; Hampton, I.; Taylor, I. Refolding, purification, and characterization of a loop deletion mutant of human Bcl-2 from bacterial inclusion bodies. Protein Expr Purif, 1999, 15, (2), 162-70.
91. Raghav, P. K. K.; Verma, Y. K. K.; Gangenahalli, G. U. Molecular dynamics simulations of the Bcl-2 protein to predict the structure of its unordered flexible loop domain. J Mol Model, 2012, 18, (5), 1885-1906.
92. Hinds, M. G.; Smits, C.; Fredericks-Short, R.; Risk, J. M.; Bailey, M.; Huang, D. C.; Day, C. L. Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ, 2007, 14, (1), 128-136.
93. Liu, X.; Dai, S.; Zhu, Y.; Marrack, P.; Kappler, J. W. The structure of a BclxL/Bim fragment complex: implications for Bim function. Immunity, 2003, 19, (3), 341-352.
94. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem, 2004, 25, (13), 1605-12.
95. Bruncko, M.; Oost, T. K.; Belli, B. A.; Ding, H.; Joseph, M. K.; Kunzer, A.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem, 2007, 50, (4), 641-662.
96. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005, 435, (7042), 677-681.
97. Petros, A. M.; Medek, A.; Nettesheim, D. G.; Kim, D. H.; Yoon, H. S.; Swift, K.; Matayoshi, E. D.; Oltersdorf, T.; Fesik, S. W. Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci U S A, 2001, 98, (6), 3012-3017.
98. Feng, W.; Huang, S.; Wu, H.; Zhang, M. Molecular basis of Bcl-xL's target recognition versatility revealed by the structure of Bcl-xL in complex with the BH3 domain of Beclin-1. J Mol Biol, 2007, 372, (1), 223-235.
99. Manion, M. K.; O'Neill, J. W.; Giedt, C. D.; Kim, K. M.; Zhang, K. Y.; Hockenbery, D. M. Bcl-XL mutations suppress cellular sensitivity to antimycin A. J Biol Chem, 2004, 279, (3), 2159-2165.
100. Petros, A. M.; Nettesheim, D. G.; Wang, Y.; Olejniczak, E. T.; Meadows, R. P.; Mack, J.; Swift, K.; Matayoshi, E. D.; Zhang, H.; Thompson, C. B.; Fesik, S. W. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. P rotein Sci, 2000, 9, (12), 2528-2534.
101. Muchmore, S. W.; Sattler, M.; Liang, H.; Meadows, R. P.; Harlan, J. E.; Yoon, H. S.; Nettesheim, D.; Chang, B. S.; Thompson, C. B.; Wong, S. L.; Ng, S. L.; Fesik, S. W. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature, 1996, 381, (6580), 335-341.
102. Denisov, A. Y. Y.; Chen, G.; Sprules, T.; Moldoveanu, T.; Beauparlant, P.; Gehring, K. Structural model of the BCL-w-BID peptide complex and its interactions with phospholipid micelles. Biochemistry, 2006, 45, (7), 2250-2256.
103. Denisov, A. Y. Y.; Madiraju, M. S.; Chen, G.; Khadir, A.; Beauparlant, P.; Attardo, G.; Shore, G. C.; Gehring, K. Solution structure of human BCL-w: modulation of ligand binding by the C-terminal helix. J Biol Chem, 2003, 278, (23), 21124-21128.
104. Hinds, M. G.; Lackmann, M.; Skea, G. L.; Harrison, P. J.; Huang, D. C.; Day, C. L. The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO J., 2003, 22, (7), 1497-1507.
105. Day, C. L.; Smits, C.; Fan, F. C.; Lee, E. F.; Fairlie, W. D.; Hinds, M. G. Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. J Mol Biol, 2008, 380, (5), 958-971.
106. Czabotar, P. E.; Lee, E. F.; Van Delft, M. F.; Day, C. L.; Smith, B. J.; Huang, D. C.; Fairlie, W. D.; Hinds, M. G.; Colman, P. M. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A, 2007, 104, (15), 6217-6222.
107. Day, C. L.; Chen, L.; Richardson, S. J.; Harrison, P. J.; Huang, D. C.; Hinds, M. G. Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem, 2005, 280, (6), 4738-4744.
108. Herman, M. D. D.; Nyman, T.; Welin, M.; Lehtiö, L.; Flodin, S.; Trésaugues, L.; Kotenyova, T.; Flores, A.; Nordlund, P. Completing the family portrait of the anti-apoptotic Bcl-2 proteins: crystal structure of human Bfl-1 in complex with Bim. FEBS Lett, 2008;582(25-26), 3590-3594.
109. Gavathiotis, E.; Suzuki, M.; Davis, M. L.; Pitter, K.; Bird, G. H.; Katz, S. G.; et al. BAX activation is initiated at a novel interaction site. Nature, 2008, 455, (7216), 1076-1081.
110. Suzuki, M.; Youle, R. J.; Tjandra, N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell, 2000, 103, (4), 645-654.
111. Lee, E. F.; Clarke, O. B.; Evangelista, M.; Feng, Z.; Speed, T. P.; Tchoubrieva, E. B.; Strasser, A.; Kalinna, B. H.; Colman, P. M.; Fairlie, W. D. Discovery and molecular characterization of a Bcl-2-regulated cell death pathway in schistosomes. Proc Natl Acad Sci U S A, 2011, 108, (17), 6999-7003.
112. Kvansakul, M.; Wei, A. H.; Fletcher, J. I.; Willis, S. N.; Chen, L.; Roberts, A. W.; Huang, D. C.; Colman, P. M. Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1. PLoS Pathog, 2010, 6, (12), e1001236.
113. Wang, H.; Takemoto, C.; Akasaka, R.; Uchikubo-Kamo, T.; Kishishita, S.; Murayama, K.; Terada, T.; Chen, L.; Liu, Z. J. J.; Wang, B. C. C.; Sugano, S.; Tanaka, A.; Inoue, M.; Kigawa, T.; Shirouzu, M.; Yokoyama, S. Novel dimerization mode of the human Bcl-2 family protein Bak, a mitochondrial apoptosis regulator. J Struct Biol, 2009, 166, (1), 32-37.
114. Kvansakul, M.; Van Delft, M. F.; Lee, E. F.; Gulbis, J. M.; Fairlie, W. D.; Huang, D. C.; Colman, P. M. A structural viral mimic of prosurvival Bcl-2: a pivotal role for sequestering proapoptotic Bax and Bak. Mol Cell, 2007, 25, (6), 933-942.
115. Moldoveanu, T.; Liu, Q.; Tocilj, A.; Watson, M.; Shore, G.; Gehring, K. The X-ray structure of a BAK homodimer reveals an inhibitory zinc binding site. Mol Cell, 2006, 24, (5), 677-688.
116. Liu, Q.; Moldoveanu, T.; Sprules, T.; Matta-Camacho, E.; Mansur-Azzam, N.; Gehring, K. Apoptotic regulation by MCL-1 through heterodimerization. J Biol Chem, 2010, 285, (25), 19615-19624.
117. Chou, J. J.; Li, H.; Salvesen, G. S.; Yuan, J.; Wagner, G. Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell, 1999, 96, (5), 615-624.
118. Bocharov, E. V.; Pustovalova, Y. E.; Pavlov, K. V.; Volynsky, P. E.; Goncharuk, M. V.; Ermolyuk, Y. S.; Karpunin, D. V.; Schulga, A. A.; Kirpichnikov, M. P.; Efremov, R. G.; Maslennikov, I. V.; Arseniev, A. S. Unique dimeric structure of BNip3 transmembrane domain suggests membrane permeabilization as a cell death trigger. J Biol Chem, 2007, 282, (22), 16256-16266.
119. Sulistijo, E. S.; Mackenzie, K. R. Structural basis for dimerization of the BNIP3 transmembrane domain. Biochemistry, 2009, 48, (23), 5106-5120.
120. Barrera-Vilarmau, S.; Obregón, P.; De Alba, E. Intrinsic order and disorder in the bcl-2 member harakiri: insights into its proapoptotic activity. PloS One, 2011, 6, (6), e21413.
121. Gerstein, M.; Krebs, W. A database of macromolecular motions. Nucleic Acids Res, 1998, 26, (18), 4280-4290.
122. Kubitzki, M. B.; Groot, B. L.; Seeliger, D. In: Protein Dynamics: From Structure to Function. Rigden D. J., Ed; Springer: Dordrecht, Netherlands, 2009; pp. 217-249.
123. Best, R. B. Atomistic molecular simulations of protein folding. Curr Opin Struct Biol, 2012, 22, (1), 52-61.
124. Karplus, M.; Kuriyan, J. Molecular dynamics and protein function. Proc Natl Acad Sci U S A, 2005, 102, (19), 6679-6685.
125. Sinha, N.; Smith-Gill, S. J. Protein structure to function via dynamics. Protein Pept Lett, 2002, 9, (5), 367-377.
126. Pinto, M.; Perez, J. J.; Rubio-Martinez, J. Molecular dynamics study of peptide segments of the BH3 domain of the proapoptotic proteins Bak, Bax, Bid and Hrk bound to the Bcl-xL and Bcl-2 proteins. J Comput Aided Mol Des, 2004, 18, (1), 13-22.
127. Acoca, S.; Cui, Q.; Shore, G. C.; Purisima, E. O. Molecular dynamics study of small molecule inhibitors of the Bcl-2 family. Proteins, 2011, 79, (9), 2624-2636.
128. Rosas-Trigueros, J. L.; Correa-Basurto, J.; Benítez-Cardoza, C.; Zamorano-Carrillo, A. Insights into the structural stability of Bax from molecular dynamics simulations at high temperatures. Protein Sci, 2011, 20, (12), 2035-2046.
129. Koshy, C.; Parthiban, M.; Sowdhamini, R. 100 ns molecular dynamics simulations to study intramolecular conformational changes in Bax. J Biomol Struct Dyn 2010, 28, (1), 71-83.
130. Mancinelli, F.; Caraglia, M.; Budillon, A.; Abbruzzese, A.; Bismuto, E. Molecular dynamics simulation and automated docking of the pro-apoptotic Bax protein and its complex with a peptide designed from the Bax-binding domain of anti-apoptotic Ku70. J Cell Biochem, 2006, 99, (1), 305-318.
131. Novak, W.; Wang, H.; Krilov, G. Role of protein flexibility in the design of Bcl-XL targeting agents: insight from molecular dynamics. J Comput Aided Mol Des, 2009, 23, (1), 49-61.
132. Lama, D.; Sankararamakrishnan, R. Anti-apoptotic Bcl-XL protein in complex with BH3 peptides of pro-apoptotic Bak, Bad, and Bim proteins: comparative molecular dynamics simulations. Proteins, 2008, 73, (2), 492-514.
133. Lama, D.; Sankararamakrishnan, R. Molecular dynamics simulations of proapoptotic BH3 peptide helices in aqueous medium: relationship between helix stability and their binding affinities to the anti-apoptotic protein Bcl-X (L). J Comput Aided Mol Des, 2011, 25, (5), 413-426.
134. Bharatham, N.; Chi, S. W. W.; Yoon, H. S. S. Molecular basis of Bcl-X (L)-p53 interaction: insights from molecular dynamics simulations. PloS One., 2011, 6, (10), e26014.
135. Eyrisch S, Helms V. Transient Pockets on Protein Surfaces Involved in Protein-Protein Interaction. J Med Chem, 2007, 50, (15), 3457-3464.
136. Rautureau, G. J.; Day, C. L.; Hinds, M. G. Intrinsically disordered proteins in bcl-2 regulated apoptosis. Int J Mol Sci, 2010, 11, (4), 1808-1824.
137. Fu, X.; Apgar, J. R.; Keating, A. E. Modeling Backbone Flexibility to Achieve Sequence Diversity: The Design of Novel α-Helical Ligands for Bcl-xL. J Mol Biol, 2007, 371, (4), 1099-1117.
138. Jiang, P.; Du, W.; Heese, K.; Wu, M. The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Mol Cell Biol, 2006, 26, (23), 9071-9082.
139. Veresov, V. G.; Davidovskii, A. I. Monte Carlo simulations of tBid association with the mitochondrial outer membrane. Eur Biophys J, 2007, 37, (1), 19-33.
140. Veresov, V. G.; Davidovskii, A. I. Activation of Bax by joint action of tBid and mitochondrial outer membrane: Monte Carlo simulations. Eur Biophys J, 2009, 38, (7), 941-960.
141. Mittag, T.; Kay, L. E.; Forman-Kay, J. D. Protein dynamics and conformational disorder in molecular recognition. J Mol Recognit, 2010, 23, (2), 105-116.
142. Mészáros, B.; Simon, I.; Dosztányi, Z. Prediction of protein binding regions in disordered proteins. PLoS Comput Biol, 2009, 5, (5), e1000376.
143. Dunker, A. K.; Obradovic, Z.; Romero, P.; Garner, E. C.; Brown, C. J. Intrinsic protein disorder in complete genomes. Genome informatics Workshop on Genome Informatics. 2000;11, 161-171.
144. Koonin, E. V.; Aravind, L. Origin and evolution of eukaryotic apoptosis: the bacterial connection. Cell Death Differ, 2002, 9, (4), 394-404.
145. Wright, P. E.; Dyson, H. J. Linking folding and binding. Curr Opin Struct Biol, 2009, 19, (1), 31-38.
146. Moroy, G.; Martin, E.; Dejaegere, A.; Stote, R. H. Molecular basis for Bcl-2 homology 3 domain recognition in the Bcl-2 protein family: identification of conserved hot spot interactions. J Biol Chem, 2009, 284, (26), 17499-17511.
147. Romero, P. R.; Zaidi, S.; Fang, Y. Y.; Uversky, V. N.; Radivojac, P.; Oldfield, C. J.; Cortese, M. S.; Sickmeier, M.; Le Gall, T.; Obradovic, Z.; Dunker, A. K. Alternative splicing in concert with protein intrinsic disorder enables increased functional diversity in multicellular organisms. Proc Natl Acad Sci U S A, 2006, 103, (22), 8390-8395.
148. Rautureau, G. J.; Day, C. L.; Hinds, M. G. Intrinsically disordered proteins in bcl-2 regulated apoptosis. Int J Mol Sci, 2010, 11, (4), 1808-1824.
149. Ryu, S. W.; Choi, K.; Park, J. H.; Park, Y. M.; Kim, S.; Choi, C. Mitofusin 1 inhibits an apoptosis-associated amino-terminal conformational change in Bax, but not its mitochondrial translocation, in a GTPase-dependent manner. Cancer Lett, 2012, 323, (1), 62-68.
150. Zheng, Y.; Zhou, M.; Ye, A.; Li, Q.; Bai, Y.; Zhang, Q. The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells. World J Surg Oncol., 2010;8, 31.
151. Kang, C. B.; Tai, J.; Chia, J.; Yoon, H. S. The flexible loop of Bcl-2 is required for molecular interaction with immunosuppressant FK-506 binding protein 38 (FKBP38). FEBS Lett, 2005, 579, (6), 1469-76.
152. Choi, B. H.; Feng, L.; Yoon, H. S. FKBP38 Protects Bcl-2 from Caspasedependent Degradation. J Biol Chem, 2010, 285, (13), 9770-9779.
153. Antonsson, B.; Martinou, J. C. The Bcl-2 protein family. Exp Cell Res, 2000, 256, (1), 50-7.
154. Dimmeler, S.; Breitschopf, K.; Haendeler, J.; Zeiher, A. M. Dephosphorylation Targets Bcl-2 for Ubiquitin-dependent Degradation: A Link between the Apoptosome and the Proteasome Pathway. J Exp Med, 1999, 189, (11), 1815-1822.
155. Ruvolo, P. P.; Deng, X.; May, W. S. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia, 2001, 15, (4), 515-22.
156. Chang, B. S.; Minn, A. J.; Muchmore, S. W.; Fesik, S. W.; Thompson, C. B. Identification of a novel regulatory domain in Bcl-X (L) and Bcl-2. EMBO J, 1997, 16, (5), 968-77.
157. Zamorano-Carrillo, A.; Zamora-López, B.; Benítez-Cardoza, C. G.; Rosas-Trigueros, J. L.; López-Camarillo, C.; Marchat, L. A. In: Advances in Genetics Research. Volume 7; Urbano K V, Ed.; Nova Science: New York, U. S. A., 2011.
158. Fussenegger, M.; Bailey, J. E.; Varner, J. A mathematical model of caspase function in apoptosis. Nat Biotechnol, 2000, 18, (7), 768-774.
159. Bagci, E. Z.; Vodovotz, Y.; Billiar, T. R.; Ermentrout, G. B.; Bahar, I. Bistability in Apoptosis: Roles of Bax, Bcl-2, and Mitochondrial Permeability Transition Pores. Biophys J, 2006, 90, (5), 1546-1559.
160. Dogu, Y.; Díaz, J. Mathematical model of a network of interaction between p53 and Bcl-2 during genotoxic-induced apoptosis. Biophys Chem, 2009;143(1-2), 44-54.
161. Rega, M. F.; Leone, M.; Jung, D.; Cotton, N. J. H.; Stebbins, J. L.; Pellecchia, M. Structure-based discovery of a new class of Bcl-xL antagonists. Bioorg Chem, 2007, 35, (4), 344-353.
162. Kazi, A.; Sun, J.; Doi, K.; Sung, S. S. S.; Takahashi, Y.; Yin, H.; Rodriguez, J. M.; Becerril, J.; Berndt, N.; Hamilton, A. D.; Wang, H. G.; Sebti, S. M. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X (L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax-and Bim-dependent manner. J Biol Chem, 2011, 286, (11), 9382-9392.
163. Dalafave, D. S.; Prisco, G. Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics. Cancer Inform, 2010;9, 169-177.
164. Ferlini, C.; Cicchillitti, L.; Raspaglio, G.; Bartollino, S.; Cimitan, S.; Bertucci, C.; Mozzetti, S.; Gallo, D.; Persico, M.; Fattorusso, C.; Campiani, G.; Scambia, G. Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77. Cancer Res, 2009, 69, (17), 6906-6914.
165. Espinoza-Fonseca, L. M.; Ilizaliturri-Flores, I.; Correa-Basurto, J. Backbone conformational preferences of an intrinsically disordered protein in solution. Mol Biosyst, 2012, 8, (6), 1798-1805.
166. Deeb, O.; Rosales-Hernández, M. C. C.; Gómez-Castro, C.; Garduño-Juárez, R.; Correa-Basurto, J. Exploration of human serum albumin binding sites by docking and molecular dynamics flexible ligand-protein interactions. Biopolymers, 2010, 93, (2), 161-170.
167. Petros, A. M.; Olejniczak, E. T.; Fesik, S. W. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta, 2004, 1644, (2-3), 83-94.
168. Clineschmidt, B. V.; Lis, E. V. Pharmacological evaluation of d (CH2) 5Tyr (Me) AVP as an antagonist of vasopressin-induced contraction of the isolated rat caudal artery. Arch Int Pharmacodyn Ther, 1986, 284, (1), 72-84.
169. Zheng, C. H.; Zhou, Y. J.; Zhu, J.; Ji, H. T.; Chen, J.; Li, Y. W.; Sheng, C.; Lu, J.; Jiang, J.; Tang, H.; Song, Y. Construction of a three-dimensional pharmacophore for Bcl-2 inhibitors by flexible docking and the multiple copy simultaneous search method. Bioorg Med Chem, 2007, 15, (19), 6407-6417.
170. Pang, X.; Moussa, S. H.; Targy, N. M.; Bose, J. L.; George, N. M.; Gries, C.; Lopez, H.; Zhang, L.; Bayles, K. W.; Young, R.; Luo, X. Active Bax and Bak are functional holins. Genes Dev, 2011, 25, (21), 2278-2290.
171. Zhou, H.; Hou, Q.; Hansen, J. L.; Hsu, Y. T. Complete activation of Bax by a single site mutation. Oncogene, 2007, 26, (50), 7092-102.